"AbbVie's ongoing HCV pipeline development program focuses on investigating a pan-genotypic, ribavirin (RBV)-free, once-daily treatment that may also allow for treatment durations of as little as eight weeks. Preliminary results from a Phase 2b study (n=79) of ABT-493 and ABT-530 in non-cirrhotic GT1 patients receiving the RBV-free recommended regimen for 12 weeks demonstrated a sustained virologic response rate at four weeks post treatment (SVR4) of 99 percent (n=78/79). These results, announced for the first time today, included both GT1a and GT1b, treatment-naïve and pegylated-interferon and RBV prior null responders.
This might be something to consider if you are not keen on riba (who is?) and have minimal or no liver damage. Hopefully the FDA will approve.
I believe it is already already approved in parts of Europe.
Course I never could wait on any tx and probably would have tried wolfbane with a 23% success rate. I'm not very patient.
http://www.prnewswire.com/news-releases/abbvie-to-present-new-data-from-hepatitis-c-clinical-
development-program-at-the-international-liver-congress-2015-300062654.html
"AbbVie's ongoing HCV pipeline development program focuses on investigating a pan-genotypic, ribavirin (RBV)-free, once-daily treatment that may also allow for treatment durations of as little as eight weeks. Preliminary results from a Phase 2b study (n=79) of ABT-493 and ABT-530 in non-cirrhotic GT1 patients receiving the RBV-free recommended regimen for 12 weeks demonstrated a sustained virologic response rate at four weeks post treatment (SVR4) of 99 percent (n=78/79). These results, announced for the first time today, included both GT1a and GT1b, treatment-naïve and pegylated-interferon and RBV prior null responders.
This might be something to consider if you are not keen on riba (who is?) and have minimal or no liver damage. Hopefully the FDA will approve.
I believe it is already already approved in parts of Europe.
Course I never could wait on any tx and probably would have tried wolfbane with a 23% success rate. I'm not very patient.
dm